Total Payments
$183,869
2024 Payments
$73,169
Companies
7
Transactions
101
Medicare Patients
2,144
Medicare Billing
$1.1M
Payment Breakdown by Category
Research$171,506 (93.3%)
Consulting$5,750 (3.1%)
Travel$4,740 (2.6%)
Food & Beverage$1,873 (1.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $171,506 | 29 | 93.3% |
| Consulting Fee | $5,750 | 1 | 3.1% |
| Travel and Lodging | $4,740 | 23 | 2.6% |
| Food and Beverage | $1,873 | 48 | 1.0% |
Payments by Type
Research
$171,506
29 transactions
General
$12,363
72 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $159,611 | 57 | $0 (2024) |
| PFIZER INC. | $21,934 | 9 | $0 (2024) |
| Nevro Corp. | $1,924 | 18 | $0 (2019) |
| AbbVie Inc. | $213.51 | 13 | $0 (2023) |
| Amgen Inc. | $123.41 | 1 | $0 (2021) |
| Medtronic USA, Inc. | $45.17 | 2 | $0 (2017) |
| SPR Therapeutics, Inc | $16.92 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $73,169 | 10 | Eli Lilly and Company ($73,107) |
| 2023 | $39,886 | 47 | PFIZER INC. ($21,872) |
| 2022 | $26,788 | 18 | Eli Lilly and Company ($26,714) |
| 2021 | $750.00 | 2 | Eli Lilly and Company ($626.59) |
| 2020 | $41,306 | 4 | Eli Lilly and Company ($41,306) |
| 2019 | $135.70 | 1 | Nevro Corp. ($135.70) |
| 2018 | $343.43 | 5 | Nevro Corp. ($343.43) |
| 2017 | $1,490 | 14 | Nevro Corp. ($1,445) |
All Payment Transactions
101 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $3.94 | General |
| Category: PAIN | ||||||
| 10/24/2024 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $6.23 | General |
| Category: PAIN | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $32,460.00 | Research |
| Study: A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $14,933.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $8,640.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $7,691.00 | Research |
| Study: A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-1) | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $7,312.00 | Research |
| Study: A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $2,071.00 | Research |
| Study: A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN | ||||||
| 05/21/2024 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $22.79 | General |
| Category: PAIN | ||||||
| 04/22/2024 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $28.77 | General |
| Category: PAIN | ||||||
| 12/07/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $4,856.40 | Research |
| Study: PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 11/21/2023 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $5,750.00 | General |
| 10/12/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $3,360.37 | Research |
| Study: PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 09/28/2023 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $343.71 | General |
| 09/28/2023 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $248.23 | General |
| 09/28/2023 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $239.38 | General |
| 09/28/2023 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $199.00 | General |
| 09/28/2023 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $176.23 | General |
| 09/28/2023 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $162.77 | General |
| 09/28/2023 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $87.20 | General |
| 09/28/2023 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $54.15 | General |
| 09/28/2023 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $31.58 | General |
| 09/28/2023 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $28.89 | General |
| 09/28/2023 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $19.90 | General |
| 09/28/2023 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $12.25 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) | Eli Lilly and Company | $32,995 | 2 |
| RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | Eli Lilly and Company | $22,089 | 3 |
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $20,394 | 1 |
| PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | PFIZER INC. | $19,868 | 4 |
| A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE | Eli Lilly and Company | $14,933 | 1 |
| RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF OSTEOARTHRITIS | Eli Lilly and Company | $10,827 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $8,640 | 1 |
| RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF CHRONIC LOW BACK PAIN | Eli Lilly and Company | $8,620 | 1 |
| A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-1) | Eli Lilly and Company | $7,691 | 1 |
| A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) | Eli Lilly and Company | $7,312 | 1 |
| A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | Eli Lilly and Company | $5,371 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $4,058 | 1 |
| A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN | Eli Lilly and Company | $2,071 | 1 |
| PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | PFIZER INC. | $2,004 | 1 |
| ASSESSMENT OF SAFETY AND EFFICACY OF SUBCUTANEOUS REMTERNETUG IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $1,358 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $1,077 | 2 |
| ASSESSMENT OF SAFETY AND EFFICACY OF INTRAVENOUS REMTERNETUG IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $641.80 | 1 |
| A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE | Eli Lilly and Company | $600.01 | 1 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $465.00 | 1 |
| Chronic Peripheral Polyneuropathy Randomized Trial | Nevro Corp. | $293.01 | 2 |
| PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 | Eli Lilly and Company | $198.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 367 | 2,826 | $1.6M | $221,609 |
| 2022 | 11 | 628 | 3,565 | $2.0M | $298,399 |
| 2021 | 7 | 536 | 3,346 | $1.7M | $300,532 |
| 2020 | 11 | 613 | 3,320 | $1.6M | $268,535 |
Total Patients
2,144
Total Services
13,057
Medicare Billing
$1.1M
Procedure Codes
33
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 127 | 1,281 | $493,185 | $126,860 | 25.7% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2023 | 123 | 1,225 | $980,000 | $72,064 | 7.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 100 | 299 | $89,700 | $21,929 | 24.4% |
| 99484 | Care management services for behavioral health conditions, 20 minutes or more clinical staff time directed by health care professional | Office | 2023 | 17 | 21 | $2,100 | $755.40 | 36.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 181 | 1,647 | $634,095 | $167,667 | 26.4% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2022 | 139 | 1,278 | $1.0M | $76,559 | 7.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 186 | 492 | $147,600 | $37,653 | 25.5% |
| 64635 | Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | Facility | 2022 | 13 | 13 | $27,352 | $3,273 | 12.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 15 | 15 | $8,925 | $2,931 | 32.8% |
| 64493 | Injection of lower or sacral spine facet joint using imaging guidance, single level | Facility | 2022 | 21 | 25 | $48,410 | $2,797 | 5.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 11 | 11 | $5,335 | $1,774 | 33.3% |
| 64483 | Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | Facility | 2022 | 13 | 15 | $23,690 | $1,705 | 7.2% |
| 64636 | Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | Facility | 2022 | 12 | 21 | $25,248 | $1,606 | 6.4% |
| 64494 | Injection of lower or sacral spine facet joint using imaging guidance, second level | Facility | 2022 | 20 | 24 | $22,660 | $1,480 | 6.5% |
| 99484 | Care management services for behavioral health conditions, 20 minutes or more clinical staff time directed by health care professional | Office | 2022 | 17 | 24 | $2,400 | $953.90 | 39.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 178 | 1,881 | $724,185 | $200,893 | 27.7% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2021 | 110 | 995 | $796,000 | $60,811 | 7.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 190 | 388 | $116,400 | $30,432 | 26.1% |
| 64635 | Destruction of lower or sacral spinal facet joint nerves using imaging guidance | Facility | 2021 | 12 | 12 | $23,144 | $3,392 | 14.7% |
| 64636 | Destruction of lower or sacral spinal facet joint nerves with imaging guidance | Facility | 2021 | 12 | 28 | $28,404 | $2,169 | 7.6% |
| 64483 | Injections of anesthetic and/or steroid drug into lower or sacral spine nerve root using imaging guidance, single level | Facility | 2021 | 13 | 18 | $25,750 | $1,901 | 7.4% |
| 99484 | Care management services for behavioral health conditions, at least 20 minutes clinical staff time | Office | 2021 | 21 | 24 | $2,400 | $933.68 | 38.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 196 | 1,996 | $613,860 | $180,115 | 29.3% |
| 80307 | Testing for presence of drug | Office | 2020 | 173 | 964 | $771,200 | $58,354 | 7.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 122 | 179 | $44,100 | $11,533 | 26.2% |
About Dr. David Dibenedetto, M.D
Dr. David Dibenedetto, M.D is a Anesthesiology healthcare provider based in Waltham, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1770599029.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Dibenedetto, M.D has received a total of $183,869 in payments from pharmaceutical and medical device companies, with $73,169 received in 2024. These payments were reported across 101 transactions from 7 companies. The most common payment nature is "" ($171,506).
As a Medicare-enrolled provider, Dibenedetto has provided services to 2,144 Medicare beneficiaries, totaling 13,057 services with total Medicare billing of $1.1M. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Ad
Practice Information
- Specialty Anesthesiology
- Other Specialties Interventional Pain Medicine
- Location Waltham, MA
- Active Since 07/31/2006
- Last Updated 02/23/2017
- Taxonomy Code 207L00000X
- Entity Type Individual
- NPI Number 1770599029
Products in Payments
- NURTEC ODT (Drug) $21,934
- Senza Spinal Cord Stimulation System (Device) $1,924
- UBRELVY (Drug) $206.66
- Aimovig (Biological) $123.41
- INTELLIS (Device) $30.02
- SPRINT PNS System (Device) $16.92
- RESTORE (Device) $15.15
- QULIPTA (Drug) $6.85
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Anesthesiology Doctors in Waltham
Lee Scott Silk, M.d, M.D
Anesthesiology — Payments: $2,548
Anesthesiology $2,548
Carlos Bazoberry, M.d, M.D
Anesthesiology — Payments: $1,274
Anesthesiology $1,274
Douglas Keene, M.d, M.D
Anesthesiology — Payments: $486.91
Anesthesiology $486.91
Steven Jay Nathin, M.d, M.D
Anesthesiology — Payments: $467.41
Anesthesiology $467.41
David Boyce, M.d, M.D
Anesthesiology — Payments: $175.47
Anesthesiology $175.47
Brent Young, M.d, M.D
Anesthesiology — Payments: $124.64
Anesthesiology $124.64